Home/Pipeline/Gilead HIV Franchise

Gilead HIV Franchise

HIV

MarketedActive

Key Facts

Indication

HIV

Phase

Marketed

Status

Active

Company

Royalty Pharma

About Royalty Pharma

Royalty Pharma is a pioneer and dominant leader in the biopharmaceutical royalty financing sector, having deployed over $25 billion in capital since its 1996 founding. Its mission is to fund the next wave of biopharma innovation by providing non-dilutive capital to partners in exchange for a share of future royalty streams. The company's strategy centers on building a diversified portfolio of royalties across therapeutic areas and development stages, leveraging deep scientific and financial expertise to structure bespoke deals that fuel R&D while generating predictable, long-duration cash flows for investors.

View full company profile

Therapeutic Areas

Oncology Cystic Fibrosis HIV Cardiovascular Autoimmune Diseases Neurology

Other HIV Drugs

Drug	Company	Phase	Status
NanoDDI	Continuity Biosciences	Pre-clinical	Active
HIV Gene Therapy	Nanite	Pre-clinical	Active
RGFields for HIV	Anapole Technologies	Clinical (phase unspecified)	Active
HIV mAb Program	Adnexus	Pre-clinical	Active
Undisclosed Program	EnnoDC	Phase 1	Active
O2-16 Series	OyaGen	Preclinical	Active
SBX 2048	Stramsen Biotech	Early-stage Clinical	Active
Undisclosed Candidates	Brii Biosciences	Phase 1	Active
ALF Platform	Senzo	Pre-clinical	Active
ANKTIVA-based regimens	ImmunityBio	Phase 1/2	Active